TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04175431

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo fluciclovine PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo fluciclovine PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo fluciclovine PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Undergo lymphadenectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO
Study: NCT00696709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: V212
Description: 0.65 mL subcutaneous injection of heat-treated Varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \~30 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: V212
Description: 0.65 mL subcutaneous injection of heat-treated Varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \~30 days apart
Study: NCT04175431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo fluciclovine PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo fluciclovine PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo fluciclovine PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PSMA PET Scan
Description: Undergo PSMA PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET scan
Study: NCT03265951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon
Description: 8 mg once daily administered within 30 minutes of bedtime

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: education brochure about sleep hygiene
Study: NCT04671498

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample

Intervention type: PROCEDURE
Intervention: Droplet-BC Test
Description: Undergo Droplet-BC Test

Intervention type: PROCEDURE
Intervention: Droplet-BC Test
Description: Undergo Droplet-BC Test

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study: NCT01360242

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MIMI procedure (two-step strategy)
Description: A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Immediate Stenting (one-step strategy)
Description: The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
Study: NCT00264745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TASK intervention
Description: The Telephone Assessment and Skill-building Kit (TASK) is an individualized 8-week intervention program geared toward reducing depression and improving general health in stroke caregivers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Minimal intervention beyond initial hospital visit.
Study: NCT04463147

Intervention type: DEVICE
Group type: OTHER
Intervention: Needle-pilotTM device
Description: The main objective aims to compare the procedure time between conventional real time ultrasound guidance and guidance with Needle-pilotTM device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Needle-pilotTM device
Description: The main objective aims to compare the procedure time between conventional real time ultrasound guidance and guidance with Needle-pilotTM device.
Study: NCT02700373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-APB

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01740752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UCAN+CBT
Description: weekly manualized couple therapy plus weekly manualized individual CBT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: weekly manualized higher dose of individual CBT
Study: NCT02293135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum Stendo session on V1 and Phantom Stendo session on V2
Description: On the firt V1 visit, the patient will receive the verum Stendo session ; then on V2 visit ((V1 + 13 days +/- 2), the patient will receive the verum Stendo session On the firt visit, V1 the patient will have a phantom Stendo session (no pressure will be applied)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phantom Stendo session on V1 and Verum Stendo session on V2
Description: On the firt V1 visit, the patient will have a phantom Stendo session (no pressure will be applied) ; then on V2 visit ((V1 + 13 dayx +/- 2), the patient will receive the verum Stendo session
Study: NCT01972243

Intervention type: OTHER
Intervention: no intervention
Study: NCT01680536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc
Study: NCT01387139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Co-administered with Propofol
Description: 0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
Study: NCT04205838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: Given via infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given via infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given via infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given via infusion
Study: NCT03709355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida®
Description: Elpida® capsules, 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida®
Description: Elpida® capsules, 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elpida®
Description: Elpida® capsules, 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elpida®
Description: Elpida® capsules, 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida®
Description: Elpida® capsules, 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida®
Description: Elpida® capsules, 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida®
Description: Elpida® capsules, 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida®
Description: Elpida® capsules, 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin capsules, 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Rifabutin capsules, 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin Film-coated tablets, 250mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole Film-coated tablets 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin Film-coated tablets, 80mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel+Ethinylestradiol
Description: Levonorgestrel 150 μg + Ethinylestradiol 30 μg, Film-coated tablets
Study: NCT03553004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Treatment
Description: Niraparib treatment by mouth (oral)
Study: NCT00999258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus
Description: The subjects assigned to the sirolimus conversion group will be initiated on sirolimus 5mg po daily at which time their tacrolimus dose will be decreased by 50%. Sirolimus levels will be checked within a week and adjusted in a linear fashion to achieve a trough goal of 12-15ng/ml in subjects within 1 year post-transplant, and 8-12 ng/ml in subjects more than 1 year post-transplant. Tacrolimus will be continued in these subjects until sirolimus target trough levels are achieved. Thereafter, tacrolimus will be discontinued indefinitely.~The subjects assigned to the tacrolimus maintenance group (control group) represent our present standard of care.

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: sirolimus
Description: The subjects assigned to the sirolimus conversion group will be initiated on sirolimus 5mg po daily at which time their tacrolimus dose will be decreased by 50%. Sirolimus levels will be checked within a week and adjusted in a linear fashion to achieve a trough goal of 12-15ng/ml in subjects within 1 year post-transplant, and 8-12 ng/ml in subjects more than 1 year post-transplant. Tacrolimus will be continued in these subjects until sirolimus target trough levels are achieved. Thereafter, tacrolimus will be discontinued indefinitely.~The subjects assigned to the tacrolimus maintenance group (control group) represent our present standard of care.
Study: NCT02352038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser therapy
Description: The test teeth will receive LLLT using a 940 nanometer diode laser (EZLASE; BIOLASE Technology Inc., Irvine, CA, USA) with output power of 330 milliwatt. The experimental side was irradiated for 30 s in two sessions, delivering an energy density of 7 Joules per square centimeter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orthodontic treatment
Description: Orthodontic treatment will be carried out using preadjusted appliances with bonded 0.022×0.028-square inch brackets/buccal tubes and 0.014-inch NiTi archwires as the first archwires. The treatment or the major part of the treatment will be completed in 12 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: orthodontic treatment
Description: Orthodontic treatment will be carried out using preadjusted appliances with bonded 0.022×0.028-square inch brackets/buccal tubes and 0.014-inch NiTi archwires as the first archwires. The treatment or the major part of the treatment will be completed in 12 months.
Study: NCT00447057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m² intravenous (iv) over 10 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg given orally (po), daily (QD), starting on the first day of the first cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg given po, QD, starting on the first day of the first cycle
Study: NCT01791725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELND005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELND005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04473885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training
Description: Participants in the experimental group will receive the balance training under perturbation on Balance SystemTM SD, including limits of stability training, maze control training, random control training. The intervention is 40 min/session, 3 sessions/week for 6 weeks.
Study: NCT04202380

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Patients will receive Azithromycin orally 1000 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Patients will receive Azithromycin orally 1000 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Ampicillin
Description: All patients will receive Ampicillin 2gm IV every 6 hours for 2 days

Intervention type: DRUG
Group type: OTHER
Intervention: Ampicillin
Description: All patients will receive Ampicillin 2gm IV every 6 hours for 2 days

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Azithromycin 500 mg orally once

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Azithromycin 250 mg orally daily for 4 days
Study: NCT02301702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap
Description: Commercially available, U.S. and Guatemala licensed, 0.5mL intramuscular injection combination tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Td
Description: The tetanus toxoid and reduced diphtheria toxoid vaccine (Td) used for this study will be the same preparation used by the National Immunization Program of Guatemala
Study: NCT03833999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: ondansetron, a 5HT3 receptor antagonist used clinically in nausea and vomiting

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: abdominal MRI
Description: serial MRIs on day 1 and day 3 of the study, at baseline and 2 hours apart 0-6 hours after meal ingestion on day 1 and 0-4 hours after the meal on day 3

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: abdominal MRI
Description: serial MRIs on day 1 and day 3 of the study, at baseline and 2 hours apart 0-6 hours after meal ingestion on day 1 and 0-4 hours after the meal on day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Participants will receive 20mls lactulose twice daily for 48 hours prior to the third study day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactulose
Description: Participants will receive 20mls lactulose twice daily for 48 hours prior to the third study day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: overcoated placebo tablet, identical to the ondansetron
Study: NCT00361140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Bu IV (BusulfexR) over 3 hours on days -6, -5, -4, and -3. Day -6 and -5 doses for patients on Level 1 will be 170mg/m2. This dose is based on the dose used by DeLima (2004) adjusted proportionately to achieve an AUC of 6000uM-min. Subsequent daily doses for patients on Level 1 will be adjusted to achieve an average AUC of 6000uM-min.~Day -6 and -5 doses for patients on Level 2 will be based on the mean dose required on Level 1 to achieve target AUC then adjusted proportionally for new target AUC.~Subsequent daily doses will be adjusted to achieve target AUCs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Bu IV (BusulfexR) over 3 hours on days -6, -5, -4, and -3. Day -6 and -5 doses for patients on Level 1 will be 170mg/m2. This dose is based on the dose used by DeLima (2004) adjusted proportionately to achieve an AUC of 6000uM-min. Subsequent daily doses for patients on Level 1 will be adjusted to achieve an average AUC of 6000uM-min.~Day -6 and -5 doses for patients on Level 2 will be based on the mean dose required on Level 1 to achieve target AUC then adjusted proportionally for new target AUC.~Subsequent daily doses will be adjusted to achieve target AUCs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Bu IV (BusulfexR) over 3 hours on days -6, -5, -4, and -3. Day -6 and -5 doses for patients on Level 1 will be 170mg/m2. This dose is based on the dose used by DeLima (2004) adjusted proportionately to achieve an AUC of 6000uM-min. Subsequent daily doses for patients on Level 1 will be adjusted to achieve an average AUC of 6000uM-min.~Day -6 and -5 doses for patients on Level 2 will be based on the mean dose required on Level 1 to achieve target AUC then adjusted proportionally for new target AUC.~Subsequent daily doses will be adjusted to achieve target AUCs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 40mg/m2 IV over 1 hour on days -6, -5, -4, and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 40mg/m2 IV over 1 hour on days -6, -5, -4, and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 40mg/m2 IV over 1 hour on days -6, -5, -4, and -3
Study: NCT02048332

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viral specific VST Infusion
Description: VSTs will be infused into stem cell transplant recipients who have evidence of viral infection or reactivation defined as any of the below:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR \>1,000~* Plasma JC Virus PCR \>1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity in one or more sites.~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies.~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy.~* Evidence of PML or other CNS infection due to JC virus.
Study: NCT01724138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Patients will start their deferasirox treatment with a dose of 20 mg/kg/day.
Study: NCT03362333

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular stabilizer muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular stabilizer muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: Pain neuroscience education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
Study: NCT03510572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain
Study: NCT01261611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: I.M. (in the muscle) injection on day 1 of up to 5 treatment cycles.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: I.M. injection on day 1 of treatment cycle 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: I.M. injection on day 1 of treatment cycle 1.
Study: NCT01429532

Intervention type: PROCEDURE
Intervention: phacoemulsification
Description: Cataract surgery performed with three incision-size-dependent phacoemulsification systems (1.8, 2.2 and 3.0 mm)

Intervention type: PROCEDURE
Intervention: phacoemulsification
Description: Cataract surgery performed with three incision-size-dependent phacoemulsification systems (1.8, 2.2 and 3.0 mm)

Intervention type: PROCEDURE
Intervention: phacoemulsification
Description: Cataract surgery performed with three incision-size-dependent phacoemulsification systems (1.8, 2.2 and 3.0 mm)
Study: NCT01625897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214
Description: Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg or 6mg) of MP-214 for four weeks, then flexible dose (1.5-9mg) of MP-214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Patients who meet eligibility criteria will be administered a once daily oral fixed dose (4mg) of risperidone for two weeks, then flexible dose (2-12mg) of risperidone
Study: NCT03369717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxi Clavulanate
Description: Postoperative antibiotics
Study: NCT03031652

Intervention type: DEVICE
Intervention: Phacoemulsification
Description: The device device used to provide and perform small profile entry for cataract extraction with or without option of insertion of a specified intraocular lens implant